R1317
R1317 is a desmethylprodine analog in which the N-methyl group is replaced by a cinnamyl group.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
R1317 is a desmethylprodine analog in which the N-methyl group is replaced by a cinnamyl group. This change in sidechain endows the compound with an increase in potency. The compound is 261 times more potent than meperidine in mice and 1100 times more potent in rats.
In another article it was stated to be 785 times more potent than meperidine. Despite this high potency, it is not the most potent 4-phenylpiperidine-reverse ester ever created. The most potent 4-phenylpiperidine-reverse ester ever created is R1480.
R1480 is stated to have a potency 1500-3180 times higher than meperidine in mice and 3040 times higher in rats. It was investigated as a candidate for a non-lethal incapacitating agent, but was discarded due to its high toxicity in primates.
The substituted 2-nitrocinnamyl, EA 2475, is 282 times more potent (analgesic potency = 28000) and have a therapeutic index superior to remifentanil, in mices, but it is highly toxic and ineffective for primates. None of these compounds were adopted as incapacitating agents, with the likely agent adopted being the EA 3382.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364832155 under CC BY-SA 4.0; modifications have been made.